Astrana HealthASTH +0.05%87 EBITDA Margin % is 5.31% as of Mar. 2026, which is 37% below its 10-year median of 8.37. GuruFocus rates ASTH with a GF Score™ of 87/100 and a GF Value™ of $82.34 (Significantly Undervalued). The stock has 8 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Astrana Health ranks worse than 65.12% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Astrana Health's EBITDA for the
three
months ended in Mar. 2026 was $51 Mil. Astrana Health's Revenue for the
three
months ended in Mar. 2026 was $965 Mil. Therefore, Astrana Health's EBITDA margin for the quarter that ended in Mar. 2026 was 5.31%.
Astrana Health (NAS:ASTH) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Astrana Health EBITDA Margin % Related Terms
Astrana Health EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Astrana Health's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASTH vs MD, SGRY, ADUS: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Astrana Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astrana Health EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Astrana Health's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Astrana Health's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astrana Health (ASTH) has a EBITDA Margin % of 5.31% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Astrana Health and its competitors. This is 37% below median its historical median of 8.37. According to the industry distribution chart, Astrana Health ranks #435 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 65.1%.
Is Astrana Health's EBITDA Margin % too high?
Astrana Health's current EBITDA Margin % of 5.31% is 37% below median its 10-year median of 8.37. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Astrana Health's value of 5.31% is 48% below this industry median. Based on the distribution chart, Astrana Health ranks #435 out of 668 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Astrana Health has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astrana Health's EBITDA Margin % compare to MD and SGRY?
According to the Healthcare Providers & Services industry distribution chart, Astrana Health ranks #435 out of 668 companies for EBITDA Margin %. This places Astrana Health in the lower half of its industry. The industry median EBITDA Margin % is 10.21. Astrana Health's value of 5.31% is 48% below this benchmark. While the company's 10-year median is 8.37 vs. the industry median of 10.21, Astrana Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astrana Health's current EBITDA Margin % of 5.31% is 48% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Astrana Health and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astrana Health's current EBITDA Margin % is 5.31%, which is 37% below median its own 10-year median of 8.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astrana Health stock overvalued right now?
Based on GuruFocus' analysis, Astrana Health (ASTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $82.34, compared to a current price of $43.50 — trading 47.2% below its estimated fair value. The current EBITDA Margin % is 5.31%, which is 37% below median its 10-year median of 8.37 and 48% below the Healthcare Providers & Services industry median of 10.21. Astrana Health's overall GF Score™ is 87/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Astrana Health (ASTH), the current EBITDA Margin % is 5.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astrana Health (ASTH) Overvalued in 2026?
Based on GuruFocus' analysis, Astrana Health stock appears to be undervalued.
The current stock price of $43.50 is trading 47.2% below its estimated GF Value™ of $82.34.
GuruFocus considers Astrana Health to be Significantly Undervalued.
Key valuation signals for ASTH:
EBITDA Margin %: 5.31% (37% below median its 10-year median of 8.37)
GF Value™: $82.34 vs. price of $43.50 (47.2% below fair value)
Industry Position: 48% below the Healthcare Providers & Services median (#435 of 668)
No single metric tells the full story. See the ASTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
87GF Score
Get the complete analysis for ASTH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASTH has been successfully added to your 
